Comparative Pharmacology
Head-to-head clinical analysis: LIVOSTIN versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVOSTIN versus TELDRIN.
LIVOSTIN vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category C
Category C
Antihistamine
Antihistamine